Increlex (Mecasermin)

Mecasermin is a recombinant form of human IGF‑1. After subcutaneous injection it circulates and binds to the IGF‑1 receptor on target cells, triggering intracellular signaling cascades such as the PI3K‑Akt and MAPK pathways. These pathways stimulate protein synthesis, cell proliferation, and bone growth, effectively replacing the missing endogenous IGF‑1.

The dose of Increlex is individualized by the prescribing clinician. Factors include the patient’s body weight, age, baseline IGF‑1 levels, and growth response. The prescriber will adjust the dose based on regular monitoring of IGF‑1 concentrations and growth parameters to achieve optimal therapeutic effect while minimizing adverse events.

Increlex is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It should be used during pregnancy only if the potential benefit justifies the potential risk. Caution is advised while breastfeeding, and the decision should be made in consultation with a healthcare professional.

To order Increlex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if required) and any necessary import documentation.

The primary alternative to Increlex is recombinant human growth hormone (somatropin). While growth hormone stimulates endogenous IGF‑1 production, Increlex directly replaces IGF‑1, making it effective in patients who lack functional growth hormone receptors or have genetic deletions. In cases of severe IGF‑1 deficiency, mecasermin provides a more direct therapeutic approach than growth hormone therapy.

Increlex must be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product is removed from refrigeration, it should be used within the time frame specified in the labeling to maintain potency.

Increlex is administered by subcutaneous injection, typically into the thigh, abdomen, or upper arm. The injection site should be rotated to reduce local irritation. Patients or caregivers should follow aseptic technique, use the appropriate needle size, and dispose of sharps in a designated container after each dose.

The most serious risks include hypoglycemia, especially if meals are missed or carbohydrate intake is insufficient; intracranial hypertension, which may present with severe headache, visual disturbances, or vomiting; and rare allergic reactions such as rash, urticaria, or anaphylaxis. Prompt medical evaluation is essential if any of these symptoms occur.

Increlex is contraindicated in individuals with known hypersensitivity to mecasermin or any component of the formulation. It should be used with caution in patients with uncontrolled diabetes, active malignancies, or pre‑existing intracranial hypertension. Pediatric patients with severe liver or kidney impairment may also be unsuitable candidates, and a clinician should assess each case individually.